What happened
William H. Carson, a board member at Annexon, Inc. (NASDAQ: ANNX), bought 34,000 common shares on Nov. 19, adding to an existing holding. For shareholders weighing the purchase, the clearest change is in the director’s own exposure: a larger holding gains or loses more for the same move in the share price.
Carson paid $3.58 per share, putting the cost of the addition at $121,720. That amount covers the new shares alone, not the value of the director’s full position. The filing, signed Nov. 20, puts the post-purchase holding at 112,405 shares, all held directly.
That balance combines the newly purchased stock with the shares Carson already owned and gives shareholders a reference point for measuring any subsequent change in the director’s direct holding.
Why it matters
The purchase is more informative when measured against what Carson already owned than in dollars alone. OptimistFi calculates that the buy lifted Carson’s holding by 43.4% from the 78,405 shares held immediately before the November transaction. The percentage measures growth in Carson’s share count, not Carson’s share of the company’s outstanding stock.
Carson made the purchase under a Rule 10b5-1 trading plan adopted July 3. That puts the adoption of the arrangement months before the shares changed hands. For shareholders weighing the trade as an insider signal, the purchase date marks the change in ownership. The trade may reflect instructions set earlier rather than a fresh judgment about Annexon on the day Carson bought the shares.
OptimistFi has argued that Annexon needs clinical or regulatory progress from its complement pipeline before financing needs dilute existing shareholders. Carson’s purchase increases one director’s exposure to that outcome and leaves the investment case unchanged.
Explain the financial terms
A Rule 10b5-1 plan is a trading plan an insider sets up in advance, while not holding inside information, that schedules later trades.
What's next
The next quarterly report is the next checkpoint for that view: clinical or regulatory progress would strengthen it, while rising financing pressure would weaken it.

